PRINCETON, N.J. & EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb. 8, 2006--Cytogen Corporation (NASDAQ: CYTO) and Savient Pharmaceuticals (NASDAQ: SVNT) announced today the execution of a binding letter of intent to negotiate a definitive agreement granting Cytogen exclusive marketing rights for SOLTAMOX(TM) (tamoxifen citrate) in the United States. SOLTAMOX, a cytostatic estrogen receptor antagonist, is the first oral liquid hormonal therapy approved in the U.S. It is indicated for the treatment of breast cancer in adjuvant and metastatic settings and to reduce the risk of breast cancer in women with ductal carcinoma in situ (DCIS) or with high risk of breast cancer.
